|
WO2020047497A1
|
|
Methods and compositions for treating stroke
|
|
WO2019226926A1
|
|
Inhibition of neurological disease
|
|
AU2016269433A1
|
|
Compositions and methods for enhancing physiological performance and recovery time
|
|
US2016041122A1
|
|
Methods and apparatus for trapping and size resolution of nanoparticles and nanobubbles
|
|
AU2015201586A1
|
|
Compositions and methods for enhancing physiological performance and recovery time
|
|
US2015202157A1
|
|
Compositions and methods for enhancing neuronal phosphorylation homeostasis, and modulating dysfunctional exocytosis and neurotransmitter release
|
|
CA2917958A1
|
|
Compositions and methods for upregulating hippocampal plasticity and hippocampus-dependent learning and memory
|
|
US2015024010A1
|
|
Methods of therapeutic treatment of eyes
|
|
US2015050343A1
|
|
Methods of wound care and treatment
|
|
AU2014203660A1
|
|
Methods of wound care and treatment
|
|
EP2986975A1
|
|
Controlling nanobubble and nanoparticle dynamics in conical nanopores
|
|
AU2014200893A1
|
|
Mixing device and output fluids of same
|
|
AU2014200002A1
|
|
Bacteriostatic or bacteriocidal compositions and methods
|
|
US2014099375A1
|
|
Methods of therapeutic treatment of eyes
|
|
US2013260462A1
|
|
Ionic aqueous solutions comprising charge-stabilized oxygen-containing nanobubbles
|
|
AU2012242592A1
|
|
Compositions and methods for inhibiting and/or modulating effector T-cells involved in inflammatory neurodegenerative disease
|
|
AU2011289172A1
|
|
Compositions and methods for treatment of taupathy
|
|
CA2808192A1
|
|
Compositions and methods for treating cardiovascular disease
|
|
BR112012028540A2
|
|
compositions and methods for improving physiological performance and recovery time
|
|
AU2011245223A1
|
|
Methods and compositions for protecting against neurotoxic agents
|
